Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

• Published in: Gastroenterology (New York, N.Y. 1943) Vol. 150; no. 1; pp. 134 - 144.e10
• Main Authors: Marcellin, Patrick, Ahn, Sang Hoon, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkashab, Magdy, Chuang, Wan-Long, Lim, Seng-Gee, Tabak, Fehmi, Mehta, Rajiv, Petersen, Joerg, Foster, Graham R., Lou, Lillian, Martins, Eduardo B., Dinh, Phillip, Lin, Lanjia, Corsa, Amoreena, Charuworn, Prista, Subramanian, G. Mani, Reiser, Hans, Reesink, Hendrick W., Fung, Scott, Strasser, Simone I., Trinh, Huy, Buti, Maria, Gaeta, Giovanni B., Hui, Aric J., Papatheodoridis, George, Flisiak, Robert, Chan, Henry L.Y.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2016
• Subjects: Administration, Oral; Adolescent; Adult; Aged; Clinical Trial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroenterology and Hepatology; HBeAg Seroconversion; HBV; Hepatitis B Surface Antigens - blood; Hepatitis B Surface Antigens - drug effects; Hepatitis B, Chronic - blood; Hepatitis B, Chronic - diagnosis; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - mortality; Humans; Injections, Subcutaneous; Interferon-alpha - therapeutic use; Internationality; Kaplan-Meier Estimate; Male; Markov Chains; Middle Aged; Polyethylene Glycols - therapeutic use; Prognosis; Recombinant Proteins - therapeutic use; Risk Assessment; Severity of Illness Index; Survival Rate; Tenofovir - therapeutic use; Treatment Outcome; Viral Load - drug effects; Virologic Response; Young Adult; Virologic Response; HBeAg Seroconversion; Clinical Trial; HBeAg; TDF; ALT; HBsAg; CHB; HBV; S/CO; peginterferon; chronic hepatitis B; sample/cutoff relative light units of quantitative HBsAg; hepatitis B surface antigen; hepatitis B virus; alanine aminotransferase; tenofovir disoproxil fumarate; hepatitis B e antigen; pegylated interferon-α

Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finit...